Diagnostics & Diseases Market Research Reports & Industry Analysis

Diagnostics involves investigating and discovering certain diseases, conditions and injuries by closely studying various symptoms and indications displayed by patients. In broad terms, today’s Diagnostics Industry breaks down into the following categories, namely in-vitro diagnostics (IVD) (examination of diverse tissue samples in a laboratory) and in-vivo diagnostics (observation and testing of tissue and any organ’s functioning by exploiting the techniques like medical (diagnostic) imaging and monitoring).

A nearly EUR 37.5 billion sector, in-vitro diagnostics promises enormous growth potential, with governments increasingly redefining soaring healthcare spending and starting to pour investments into the high tech diagnostics business. The latter continues to be superintended by a mere scattering of behemoths. Major forces fuelling the industry development include, among others, innovative approaches regarding equipment and clinical trial activities.

This Catalogue presents an invaluable collection of research reports examining the Diagnostics and Diseases Market worldwide, by various regions and selected countries. The research reports feature market sizing analyses and growth rate reviews, discussions of factors diving or deterring the growth of the Diagnostics and Diseases Industry, information on market dynamics and share, etc. The profiles of large-to-micro caps, and the Diagnostics and Diseases Market forecasts are provided in the research reports too.

Found 5276 publications
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023”. ... Medicines Agency (EMA) in 2008, for use in locally-advanced or metastatic breast cancer, in combination with Xeloda (capecitabine). In 2010, the FDA and ...

Sep, 2014 55 pages
PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

... the high treatment rates in the neoadjuvant and adjuvant settings using HER2-targeted therapies in all stages, have helped drive the sales ... afford to reimburse the latest expensive drugs. Scope An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology ...

Sep, 2014 165 pages
PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

... covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. Analysis of unmet needs within the ... sizing, forecasts and quantified growth opportunities in the Japan HER2-Positive Breast Cancer market through 2018. Quantify candidate patient populations ...

Sep, 2014 158 pages
PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 US$ 4,995.00

... covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. Analysis of unmet needs within the ... sizing, forecasts and quantified growth opportunities in the China HER2-Positive Breast Cancer market through 2018. Quantify candidate patient populations ...

Sep, 2014 154 pages
PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

... , Herceptin is the market leader in France, since it was the first HER2-targeting agent to market. Newly-approved drugs tend to gain market ... approved for use in this setting in the US. Scope An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology ...

Sep, 2014 196 pages
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 ... , unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease ...

Sep, 2014 54 pages
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023”. ... , unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease ...

Sep, 2014 65 pages
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 ... 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked ...

Sep, 2014 54 pages
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023”. ... , unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease ...

Sep, 2014 58 pages
Global Molecular Spectroscopy Market 2014-2018 US$ 2,500.00

... TechNavio's report, Global Molecular Spectroscopy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry ... VENDORS ABB Bomem FOSS Jasco Jeol Shimadzu Spectrolab Systems MARKET DRIVER Increase in Use of Hyper-sophisticated Equipment in Food and Beverages ...

Oct, 2014 84 pages
Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) US$ 800.00

Scope of the Report The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the ... of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues ( ...

Sep, 2014 66 pages
Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research,... US$ 4,515.00

... diseases and myogenic disorders. The oncology segment leads the market and is followed by infectious diseases due to the rising incidence of these ... in the supply chain of the DNA diagnostics market MARKET SEGMENTATION: The DNA diagnostics market is segmented based on product type, technology, application ...

Aug, 2014 170 pages
Ventricular Septal Defect Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Ventricular Septal Defect clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 57 pages
Venous (Vein) Thrombosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Venous (Vein) Thrombosis clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 193 pages
Vasospastic Angina Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Vasospastic Angina. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 56 pages
Vascular Calcification Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Vascular Calcification. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 58 pages
Unstable Angina Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Unstable Angina. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 109 pages
Thrombosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 Summary GlobalData's clinical trial report, “Thrombosis Global Clinical Trials Review, H2, 2014' provides data on the Thrombosis clinical trial scenario. This ... type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / ...

Sep, 2014 154 pages
Cedar Pollen Allergy Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Cedar Pollen Allergy clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 64 pages
Cat Allergy Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Cat Allergy. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 62 pages
Birch Pollen Allergy Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Birch Pollen Allergy clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 77 pages
Behcet's Disease Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Behcet’s Disease. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 79 pages
Axial Spondyloarthritis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 97 pages
Anca Vasculitis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Anca Vasculitis. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 68 pages
Global Cancer Kinase Inhibitors Market & Pipeline Insight US$ 2,400.00

... of host effector mechanisms which tend to lead to better therapeutic targets. “Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight: Classification & Mechanism of Kinase Inhibitors Cancer Kinase Inhibitors Therapy Market Overview Cancer Kinase Inhibitors Therapy Pipeline by Phase ...

Oct, 2014 1500 pages
Molecular Diagnostics Partnering Terms and Agreements US$ 1,995.00

The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics ... a review of the leading molecular diagnostics deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most ...

Oct, 2014 432 pages
Global Cancer Monoclonal Antibodies Market & Pipeline Insight US$ 2,400.00

... milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has ... of the human cells there is still significant work which needs to be done. “Global Cancer Monoclonal Antibodies Market & Pipeline Insight” Report highlights: ...

Oct, 2014 1400 pages
RNA Analysis/Transcriptomics Market by Technology (Microarray, PCR, NGS, RNAi), by Application (Clinical Diagnostics, Drug Discovery, Toxicogenomics), by End-User (Academic Research,... US$ 4,650.00

... of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown in the past few years primarily ... offered by the top players in the transcriptomics market. The report analyzes the transcriptomics market by technology, application, end-user and geography ...

Sep, 2014 192 pages
Tosoh: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 3,850.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Tosoh and its main competitors, as well as a profile of ...

Oct, 2014 28 pages
Sysmex: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 4,850.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Sysmex and its main competitors, as well as a profile of the ...

Oct, 2014 43 pages
Quidel: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 1,450.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Quidel and its main competitors, as well as a profile of the ...

Oct, 2014 7 pages
DiaSorin: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 6,500.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for DiaSorin and its main competitors, as well as a profile of the ...

Oct, 2014 54 pages
Thermo Fisher: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 4,250.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Thermo Fisher and its main competitors, as well as a profile of ...

Oct, 2014 43 pages
Ortho-Clinical Diagnostics: Sales, Market Shares and Competitive Position by Product and Country US$ 3,850.00

... from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Ortho-Clinical Diagnostics and its main competitors, as well as a profile ...

Oct, 2014 74 pages
Immucor: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 2,450.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Immucor and its main competitors, as well as a profile of the ...

Oct, 2014 17 pages
Global Pancreatic Cancer Market 2014-2018 US$ 2,500.00

... outlines the challenges faced by the vendors. TechNavio's report, the Global Pancreatic Cancer market 2014-2018, has been prepared based on an in-depth ... . The report also includes a discussion of the key vendors operating in this market. Key Regions Americas APAC EMEA Key Vendors Celgene Eli ...

Oct, 2014 97 pages
Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018 US$ 2,500.00

... COPD is a broad term that covers various progressive lung diseases including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some ... five: Medications, Oxygen Therapy, Surgery, Pulmonary Rehabilitation, and Lifestyle Changes. TechNavio's report, the Global COPD Market 2014-2018, has ...

Oct, 2014 79 pages
Grifols: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 3,250.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Grifols and its main competitors, as well as a profile of the ...

Sep, 2014 21 pages
Gen-Probe/Hologic: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 4,500.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Gen-Probe/Hologic and its main competitors, as well as a profile of ...

Sep, 2014 26 pages
Diagnostica Stago: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 3,450.00

... from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Diagnostica Stago and its main competitors, as well as a profile of ...

Sep, 2014 25 pages
Bio-Rad: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 3,750.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Bio-Rad and its main competitors, as well as a profile ...

Sep, 2014 70 pages
bioMerieux: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 5,450.00

... not available from any other published source. The report includes diagnostics sales and market share estimates by product and country bioMerieux and its main competitors, as well as a profile of the companys diagnostics business. Contains 115 pages and 112 tables

Sep, 2014 115 pages
Becton Dickinson: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 4,750.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Becton Dickinson and its main competitors, as well as a profile ...

Sep, 2014 105 pages
Beckman Coulter: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 4,750.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Beckman Coulter and its main competitors, as well as a profile ...

Sep, 2014 111 pages
Physician Views: New data for Novartis' LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market? US$ 645.00

... in the 6.5 million EU patients, looks increasingly conservative in the light of presented data,' Parry added. Novartis itself is doing little to lower expectations about ... play a role in the company's price-setting calculus. Based on the new data, JP Morgan analyst Richard Vosser believes LCZ696 has 'multi- ...

Physician Views: The PD-1 inhibitor class lands – how do US oncologists expect to initially use Merck & Co.'s Keytruda? US$ 645.00

... Yervoy (ipilimumab) and, if BRAF V600-mutation positive, a BRAF inhibitor (see also Physician Views Poll Results – Oncologists suggest Mekinist/Tafinlar combination ... of a multi-billion dollar market over the next decade – this Physician Views poll contains a second component that provides oncologist assessment ...

Sep, 2014
Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape? US$ 645.00

... trial showing the drug improved progression-free survival (PFS) by 18.6 months when added to Femara in postmenopausal women with oestrogen receptor (ER) positive, HER2- ... Phase III) and Avastin (accelerated approval based on PFS later revoked when it did not improve OS), would the FDA be right to wait for data ...

Aug, 2014
Abbott: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 8,500.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Abbott and its main competitors, as well as a profile of the ...

Sep, 2014 214 pages
Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation US$ 6,995.00

... and enable marketing executives to strategize their product launches, by allowing them to: Understanding of the focal shifts in molecular targets in the breast cancer pipeline. Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target. Access a ...

Jul, 2014 116 pages
Siemens: Diagnostics Sales, Market Shares and Competitive Position by Product and Country US$ 7,500.00

... report from Venture Planning Group provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for Siemens and its main competitors, as well as a profile of the ...

Sep, 2014 179 pages
1 2 3 4 5 >
Skip to top